Evidence map›Paper›PMID 12878531›Full record

ArticleAntimicrobial agents and chemotherapy2003

Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp.

Sevtap Arikan, Pinar Yurdakul, Gulsen Hascelik

Abstract readComparative Study
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Methods forJournal of pharmaceutical analysis · 2016
    Review
  5. Article
  6. Review of the pharmacology and clinical studies of micafungin.Drug design, development and therapy · 2009
    Article
  7. Article
  8. Anidulafungin and its role in candida infections.Infection and drug resistance · 2009
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sevtap ArikanDepartment of Microbiology and Clinical Microbiology, Faculty of Medicine, Hacettepe University, 06100 Ankara, Turkey. sarikan@metu.edu.tr
Pinar Yurdakul
Gulsen Hascelik

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the in vitro activity of micafungin against clinical Aspergillus isolates (n = 37) (Aspergillusfumigatus [n = 21], Aspergillusflavus [n = 14], and Aspergillus niger [n = 2]) by using NCCLS M38A microdilution and an investigational disk diffusion assay. Microdilution assay results were evaluated by using the end points of a MIC-2 (measured in micrograms per milliliter) and minimum effective concentration (MEC, measured in micrograms per milliliter; the lowest concentration of micafungin that produces short and aberrant hyphal branchings microscopically). Disk diffusion results were interpreted by measuring the zone(s) of inhibition (ZOI, measured in millimeters). Micafungin proved to be similarly active against all Aspergillus species tested. At 24 h, MIC-2s and MECs were identical. At 48 h, however, MIC-2s increased unpredictably, leading to the loss of a consistent correlation between the two end points. MECs and ZOI remained consistent and correlated at both reading times, suggesting their use as relevant end points in susceptibility testing of micafungin against Aspergillus: All Aspergillus isolates yielded intrazonal growth on disk diffusion agar plates. The intrazonal colonies contained short, aberrant hyphal branchings microscopically. The in vivo significance of these findings remains to be further investigated.

Indexed as

Antifungal AgentsAspergillusDiffusionEchinocandinsEndpoint DeterminationHyphaeIndicator Dilution TechniquesLipopeptidesLipoproteinsMicafunginMicrobial Sensitivity TestsPeptides, CyclicAntifungal AgentsEchinocandinsLipopeptidesLipoproteinsMicafunginPeptides, Cyclic

Identifiers

PMID12878531
PMCPMC166107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.